ATE554184T1 - Durch das nukleäre aminoxidase-homolog lsd1 vermittelte histondemethylierung - Google Patents

Durch das nukleäre aminoxidase-homolog lsd1 vermittelte histondemethylierung

Info

Publication number
ATE554184T1
ATE554184T1 AT05857133T AT05857133T ATE554184T1 AT E554184 T1 ATE554184 T1 AT E554184T1 AT 05857133 T AT05857133 T AT 05857133T AT 05857133 T AT05857133 T AT 05857133T AT E554184 T1 ATE554184 T1 AT E554184T1
Authority
AT
Austria
Prior art keywords
lsd1
histone
lysine
methylation
histone demethylation
Prior art date
Application number
AT05857133T
Other languages
English (en)
Inventor
Yang Shi
Yujiang Shi
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36615404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE554184(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE554184T1 publication Critical patent/ATE554184T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT05857133T 2004-12-16 2005-12-16 Durch das nukleäre aminoxidase-homolog lsd1 vermittelte histondemethylierung ATE554184T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63609504P 2004-12-16 2004-12-16
PCT/US2005/045987 WO2006071608A2 (en) 2004-12-16 2005-12-16 Histone demethylation mediated by the nuclear amine oxidase homolog lsd1

Publications (1)

Publication Number Publication Date
ATE554184T1 true ATE554184T1 (de) 2012-05-15

Family

ID=36615404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05857133T ATE554184T1 (de) 2004-12-16 2005-12-16 Durch das nukleäre aminoxidase-homolog lsd1 vermittelte histondemethylierung

Country Status (6)

Country Link
US (3) US7741086B2 (de)
EP (1) EP1833981B1 (de)
AT (1) ATE554184T1 (de)
AU (1) AU2005322312B2 (de)
CA (1) CA2591717A1 (de)
WO (1) WO2006071608A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693062A3 (de) * 2005-02-18 2007-12-12 Universitätsklinikum Freiburg Kontrolle der Androgen-Receptor abhängigen Gen-Exprimierung
ATE489624T1 (de) * 2005-04-29 2010-12-15 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
US7858395B2 (en) 2005-07-13 2010-12-28 Universitaetsklinikum Freiburg Antibodies for use in identifying and/or scoring prostate cancer and androgen receptor-dependent gene expression control
CA2619005A1 (en) 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
WO2009015283A2 (en) * 2007-07-24 2009-01-29 President And Fellows Of Harvard College Bhc80 - histone complexes and uses thereof
WO2010011845A2 (en) 2008-07-24 2010-01-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of preventing or treating viral infection or reactivation after latency in a host using inhibitors of the lsd1 protein
EP2361242B1 (de) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidaseinhibitoren und deren verwendung
BRPI0922572A2 (pt) 2008-12-17 2019-09-24 Scripps Research Inst método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
EP2258858A1 (de) * 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Für LSD1 transgenisches Tiermodell für Krebs
US20110021362A1 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011096196A1 (en) * 2010-02-02 2011-08-11 Oncotherapy Science, Inc. Lsd1 for target genes of cancer therapy and diagnosis
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
US8593253B2 (en) * 2010-06-09 2013-11-26 Gm Global Technology Operations, Inc. Systems and methods for efficient authentication
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
EP2598480B1 (de) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylaminderivate als lsd1-hemmer
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US20130303545A1 (en) * 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) * 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CA2841710C (en) 2011-07-15 2021-03-16 The General Hospital Corporation Methods of transcription activator like effector assembly
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
RU2668952C2 (ru) 2011-10-20 2018-10-05 Оризон Дженомикс, С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
MX356344B (es) 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3789405A1 (de) * 2012-10-12 2021-03-10 The General Hospital Corporation Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
WO2014085613A1 (en) 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
AU2014214719B2 (en) 2013-02-07 2020-02-13 The General Hospital Corporation Tale transcriptional activators
US9909132B2 (en) 2013-04-09 2018-03-06 Chris Tuttle Formulations and methods for control of weedy species
KR101601940B1 (ko) 2014-02-28 2016-03-09 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 kdm1b
KR101601943B1 (ko) 2014-02-28 2016-03-09 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 uchl1
KR101601942B1 (ko) 2014-02-28 2016-03-09 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 tet1
KR101601941B1 (ko) 2014-02-28 2016-03-09 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 mta3
KR101583673B1 (ko) 2014-02-28 2016-01-08 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 dlx5
EP3090998A1 (de) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Feste formen
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CN109462980B (zh) 2016-03-15 2022-02-08 奥莱松基因组股份有限公司 用于治疗血液恶性肿瘤的lsd1抑制剂的组合
RS58951B1 (sr) 2016-06-10 2019-08-30 Oryzon Genomics Sa Lečenje multiple skleroze
CA3035806A1 (en) * 2016-09-07 2018-03-15 University Of Canberra Lysine specific histone demethylase-1 inhibitors and uses therefor
US20200069677A1 (en) 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
WO2019075327A1 (en) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
CN110988329A (zh) * 2019-12-23 2020-04-10 贞丰县人民医院 一种β-羟丁酸或其药学上可接受的盐的用途
CN112098448B (zh) * 2020-08-14 2022-05-20 深圳大学 基于核磁共振氢谱的lsd1的活性检测方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900306B2 (en) * 2001-08-01 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of CoREST expression
EP1693383B1 (de) 2005-02-18 2013-10-09 Universitätsklinikum Freiburg Antikörper zur Erkennung von Prostatakrebs
DE602005022826D1 (de) 2005-02-18 2010-09-23 Universitaetsklinikum Freiburg Kontrolle der Androgen Rezeptor-abhängigen Gen Expression durch Hemmung der Aminoxidase Aktivität der Lysin spezifischen Demethylase (LSD1)

Also Published As

Publication number Publication date
CA2591717A1 (en) 2006-07-06
US7741086B2 (en) 2010-06-22
WO2006071608A2 (en) 2006-07-06
US8323941B2 (en) 2012-12-04
EP1833981B1 (de) 2012-04-18
EP1833981A2 (de) 2007-09-19
US20100240733A1 (en) 2010-09-23
AU2005322312B2 (en) 2011-05-26
AU2005322312A1 (en) 2006-07-06
US20090170796A1 (en) 2009-07-02
US20130210888A1 (en) 2013-08-15
WO2006071608A3 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
ATE554184T1 (de) Durch das nukleäre aminoxidase-homolog lsd1 vermittelte histondemethylierung
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
TR201904660T4 (tr) İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri.
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
EA201390740A1 (ru) Способ лечения с использованием ингибитора braf
MA54758A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EA201201640A1 (ru) Способы определения устойчивости рака к ингибиторам гистондеацетилазы
BRPI0721343A2 (pt) Composição, métodos para prevenir ou tratar obesidade em um animal sem perda concomitante de massa de músculo magro, para a preservação de massa de músculo magro em um animal, e para o ganho de massa de músculo magro em um animal, e, uso das composições.
MX2018011012A (es) Formulaciones y dosis de uricasa pegilada.
BRPI0813926A2 (pt) Utilização de uma substância, composição e métodos de triagem de princípios ativos que inibem a formação dos ages e de cuidado cosmético.
MA55716A (fr) Inhibiteurs de dihydroorotate déshydrogénase
MX2009012315A (es) Metodos de identificacion de genes involucrados en la formacion de memoria utilizando arn pequeño de interferencia (arnip).
BRPI0713503A2 (pt) Promotor sintético induzível por patógeno
CL2012000869A1 (es) Composicion que comprende cepa seleccionada de lactobacillus plantarum cect 7527, o cepas mutantes de la misma; uso de una composicion para prevenir y/o tratar transtornos cardiovasculares.
EA202190752A1 (ru) Получение ингибитора семикарбазид-чувствительной аминоксидазы и его применение
MA54695A (fr) Inhibiteurs de dihydroorotate déshydrogénase
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
ATE476970T1 (de) Kontrolle der androgen rezeptor-abhängigen gen expression durch hemmung der aminoxidase aktivität der lysin spezifischen demethylase (lsd1)
MX2022012000A (es) Inhibidores de c5a para el tratamiento de infeccion por coronavirus.
EP4051798A4 (de) Rnai-mittel zum hemmen der expression von beta-enac, zusammensetzungen davon und verfahren zur verwendung
BR112017024394A2 (pt) inibidores gata-3 para uso no tratamento da asma conduzida por th2
EA201200514A1 (ru) Применение 4-[этил(диметил)аммонио]бутаноата для лечения сердечно-сосудистых заболеваний
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
TNSN07364A1 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders